Is it safe?
Can INDV take a bad year?
Indivior Pharmaceuticals, Inc. carries $265M of net debt at 0.62× EBITDA: a load its earnings can carry.
$265M
Net debt · as at Q2 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 0.62×
Net debt / EBITDA · −0.79× a year ago · the load is going up
- Altman Z-score
- 3.46
Altman Z-score · safe zone, above 3
- Cash runway
- 2.0 years
Cash runway · burning $28M a quarter at the current rate
Details›
- Total debtQ2 2026
- $487M
- Cash and short-term investments
- $222M
- Net debt
- $265M
- EBITDA, trailing twelve months
- $430M
- Operating profit, trailing twelve months
- $421M
- Total debt / EBITDA
- 1.13×
- Annualised volatilitytwo years of daily moves
- 49%
- Worst drawdown on file
- −94%
- Below its 52-week high
- −14%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers - Specialty & Generic
Ranks #23 of 28 by Smart Score